Overview

Management of Decompensated HCV Cirrhotic Patients

Status:
Completed
Trial end date:
2018-06-24
Target enrollment:
0
Participant gender:
All
Summary
-The limited treatment varieties of decompensated cirrhosis due to hepatitis C virus (HCV) remain a challenge. In patients with reduced hepatic reserve, DAAs may be associated with complications as worsening decompensation. The impact of DAAs therapy on mortality in decompensated cirrhosis was not investigated.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Zagazig University
Treatments:
Antiviral Agents
Furosemide
Ribavirin
Silymarin
Sofosbuvir
Spironolactone
Vitamin K
Vitamin K 1
Criteria
Inclusion Criteria:

- chronic active HCV proved by the positivity of HCV RNA, elevated transaminases.

- CTP score was >9, MELD score was <29

- Decompensated cirrhosis with frequent hepatic encephalopathy (HE) or difficult to
treat ascites

Exclusion Criteria:

- exposure to previous antiviral therapy

- hepatocellular carcinoma

- other causes of liver diseases or mixed causes (excessive alcohol consumption,
autoimmune liver disease)

- previous liver transplantation.